FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	

	OMB Number:	3235-0287
ı	Estimated average burden	
ı	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address <u>Douglas Rober</u>			2. Issuer Name and Ticker or Trading Symbol RESMED INC [RMD]		ionship of Reporting Per all applicable) Director	rson(s) to Issuer
(Last) RESMED INC.	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/01/2013	X	Officer (give title below) President and CO	Other (specify below) O ResMed Inc.
9001 SPECTRUM CENTER BLVD. (Street) SAN DIEGO CA 92123		92123	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi	g (Check Applicable Line) porting Person an One Reporting Person	
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)				Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
			Code	v		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
ResMed Common Stock	04/01/2013(1)		M		7,500	A	\$21.025	106,330.588	D	
ResMed Common Stock	04/01/2013(1)		S		7,500	D	\$46.163(3)	98,830.588	D	
ResMed Common Stock	04/01/2013(1)		S		500	D	\$46.67	98,330.588	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Num Deriva Secur Acqui or Dis of (D) 4 and	tive ties red (A) posed (Instr. 3,	6. Date Exerci Expiration Dat (Month/Day/Yo	te	7. Title and An Securities Und Derivative Sec 3 and 4)	derlying	Derivative	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
ResMed Common Stock Options	\$21.025	04/01/2013 ⁽¹⁾		M			7,500	11/07/2008 ⁽²⁾	11/07/2014	ResMed Common Stock	7,500	\$0	75,000	D	

Explanation of Responses:

- 1. Trade executed pursuant to a 10b5-1 trading plan.
- 2. Represents date options first became exercisable. Options vest 1/4 per year on the anniversary of the grant.
- 3. This transaction was executed in multiple trades at prices ranging from \$45.96 to \$46.62. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.

Remarks:

Robert Douglas, President and Chief Operating Officer, ResMed 04/03/2013 Inc. 04/03/2013

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.